TABLE 1.
Clinical and demographical information about the study subjectsa
| Subject | Eth- nicity | Gender | Risk factor | Plasma viral load (RNA copies/ml)b | CD4-cell counts (cells/mm3)b | Treatment |
|---|---|---|---|---|---|---|
| AC 21 | C | m | msm | <50 | 990 | HAART |
| AC 31 | C | m | msm | <50 | 676 | HAART |
| AC 32 | C | m | msm | <50 | 467 | HAART |
| AC 34 | C | m | msm | <50 | 304 | HAART |
| AC 43 | C | m | msm | <50 | 530 | HAART |
| AC 52 | C | m | msm | <50 | 367 | HAART |
| AC 68 | C | m | msm | <50 | 389 | HAART |
| AC 85 | C | m | msm | <50 | 1,023 | HAART |
| AC 88 | C | m | msm | <50 | 365 | HAART |
| AC 100 | C | m | msm | 1570 | 801 | HAART |
| AC 101 | C | m | msm | 3,580 | 426 | HAART |
| AC 04 | C | m | msm | <50 | 799 | STI/on HAART |
| AC 05 | C | m | msm | 14,200 | 465 | STI/off HAART |
| AC 06 | C | m | msm | 63,380 | 605 | STI/off HAART |
| AC 14 | C | m | msm | 1,510 | 1,017 | STI/on HAART |
| AC 15 | C | m | msm | 80 | 555 | STI/on HAART |
| AC 16 | C | m | msm | 196 | 1,004 | STI/off HAART |
| AC 25 | C | m | msm | 7,680 | 520 | STI/off HAART |
| AC 26 | C | m | msm | <50 | 770 | STI/on HAART |
| AC 34 | C | m | msm | 505 | 631 | STI/off HAART |
| AC 45 | C | m | msm | 81 | 477 | STI/on HAART |
| AC 46 | C | m | msm | <50 | 772 | STI/on HAART |
| CHR-1 | C | m | msm | <50 | 823 | HAART |
| CHR-2 | C | m | msm | <50 | 828 | HAART |
| CHR-3 | C | m | msm | <50 | 597 | HAART |
| CHR-4 | C | m | msm | <50 | 239 | HAART |
| CHR-5 | C | m | msm | 73 | 89 | HAART |
| CHR-6 | C | m | msm | <50 | 707 | HAART |
| CHR-7 | C | f | hetero | <50 | 561 | HAART |
| CHR-8 | C | m | msm | <50 | 852 | HAART |
| CHR-9 | C | f | hetero | 80 | 385 | HAART |
| CHR-10 | C | m | msm | <50 | 246 | HAART |
| CHR-11 | C | m | msm | <50 | 396 | HAART |
| CHR-12 | C | m | msm | <50 | 430 | HAART |
| CHR-13 | C | m | msm | 7190 | 770 | None |
| CHR-14 | AA | m | hetero | 141,000 | 142 | None |
| CHR-15 | C | m | msm | 3,900 | 549 | None |
| CHR-16 | C | m | msm | 7,980 | 641 | None |
| CHR-17 | H | m | msm | 6,200 | 653 | None |
| CHR-18 | C | m | msm | 97,400 | 813 | None |
| CHR-19 | AA | m | hetero | 3,960 | 449 | None |
| CHR-20 | C | f | hetero | 41,600 | 410 | None |
| CHR-21 | H | f | hetero | 49,200 | 730 | None |
| CHR-22 | C | m | msm | 187,000 | 253 | None |
| CHR-23 | C | f | hetero | 73,700 | 259 | None |
| CHR-24 | C | m | msm | 53,863 | 186 | None |
| CHR-25 | C | m | hetero | 300,000 | 43 | None |
| CHR-26 | C | f | ivdu | 2,230 | 420 | None |
| CHR-27 | C | m | hemo | <50 | 523 | None |
| CHR-28 | C | m | msm | <50 | 875 | None |
| CHR-29 | C | m | msm | 876 | 843 | None |
| CHR-30 | C | m | msm | 1,412 | 1,020 | None |
| CHR-31 | C | m | msm | 132 | 930 | None |
| CHR-32 | C | m | msm | 800 | 670 | None |
| CHR-33 | C | m | msm | 980 | 720 | None |
| CHR-34 | C | m | msm | 738 | 597 | None |
| CHR-35 | C | m | msm | <50 | 540 | None |
a
AC, acute; CHR, chronic; C, caucasian; AA, African American; H, Hispanic; m, male; f, female; msm, men having sex with men; hetero, heterosexual contact; ivdu, IV drug use; hemo, hemophiliac; HAART, highly active antiretroviral therapy.
b
Measured at time of HIV-1-specific T-cell analysis.